Providers March on U.S. Capitol Grounds to “Defend 340B”

Safety-net provider advocates marched on the U.S. Capitol grounds yesterday to raise awareness about threats to the 340B drug pricing program.

About 100 safety-net provider advocates marched and chanted yesterday on the grounds of the U.S. Capitol to raise awareness in Congress and beyond about threats to the 340B drug pricing program.

Please Login or

Read More »

Ex-Surgeon General Adams Urges 340B Entities to Publicize Program’s Benefits

Ex-U.S. Surgeon General Jerome Adams urged 340B Coalition summer conference attendees to show they "are fighting to deliver care to the vulnerable and to the underserved." | Credit: 340B Coalition Twitter

Healthcare providers can suppress attacks on and build support for the 340B program by doing more to show the program helps vulnerable patients, the anesthesiologist who served as President Trump’s surgeon general said yesterday.

Read More »

340B Hospitals Ask Judge to Stop Part B Drug Payment Cuts Immediately

Groups that represent 340B hospitals asked a federal district judge to immediately halt a nearly 30% Medicare Part B payment cut for hospitals’ 340B-purchased drugs.

Groups that represent 340B hospitals yesterday asked a federal district judge in Washington, D.C., to immediately halt a nearly 30% Medicare Part B payment cut in place since 2018 for hospitals’ 340B-purchased drugs.

Please

Read More »

Purdue Pharma Is Providing 340B Refunds Spanning 16 Years of Overcharges

Purdue Pharma announced refunds for 340B overcharges on Betasept antiseptic surgical scrub for purchases spanning 16 years—more than half of the 340B program's existence.

Purdue Pharma’s Avrio Health subsidiary is giving 340B covered entities refunds for overcharges on Betasept antiseptic surgical scrub for purchases spanning 16 years—from Q2 2005 through Q2 2021.

Please Login or Become a Paid Subscriber to

Read More »

Senate Democrats Say They Are on Track to Pass Drug Pricing Bill Before Aug. 8

Senate Democrats are still pushing to pass drug pricing legislation before the chamber begins its summer break on Aug. 8.

Senate Democrats said yesterday they would know this week whether an updated Senate drug pricing bill meets the criteria for passage via budget reconciliation, which requires just 50 Democratic votes.

Please Login or Become a Paid

Read More »

HRSA Unveils New 340B Contract Pharmacy Services Webpage That Is Silent on Manufacturer Obligations

HRSA has posted a new 340B Contract Pharmacy Services webpage that addresses requirements for covered entities but not for pharmaceutical manufacturers.

The U.S. Health Resources and Services Administration overnight posted a new Contract Pharmacy Services page on the 340B program website that addresses requirements for covered entities but not for pharmaceutical manufacturers.

Please Login or

Read More »

A Blizzard in July (of Briefs in 340B Contract Pharmacy Lawsuits)

Multiple briefs have been filed recently in federal appellate lawsuits over the government's enforcement ability with the 340B contract pharmacy program.

There’s been a burst of activity in federal appellate lawsuits over the legality of drug manufacturers’ conditions on 340B pricing involving contract pharmacies.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Biden Administration Kills Trump-era Rules Casting Doubt on HHS Guidance and Enforcement Actions

The Biden administration repealed Trump-era rules that it said hindered HHS from issuing guidance and bringing enforcement actions.

The Biden administration yesterday repealed Trump administration final rules that it said hindered the U.S. Health and Human Services Department’s (HHS) ability “to issue guidance, bring enforcement actions, and take other appropriate actions that advance the department’s mission.”

Read More »

340B Report Publisher and CEO: What to Expect Following Midterm Elections

Look for the GOP to try again to put more restrictions on the 340B program if the party takes over the U.S. House, 340B Report Publisher and CEO Ted Slafsky says.

Congress’ attitude toward the 340B program will likely change in 2023 and 2024 because of November’s midterm election results, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

Please

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report